Oliver Schadt

405 total citations
17 papers, 319 citations indexed

About

Oliver Schadt is a scholar working on Molecular Biology, Oncology and Hepatology. According to data from OpenAlex, Oliver Schadt has authored 17 papers receiving a total of 319 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Oncology and 7 papers in Hepatology. Recurrent topics in Oliver Schadt's work include Liver physiology and pathology (7 papers), Ubiquitin and proteasome pathways (6 papers) and Peptidase Inhibition and Analysis (4 papers). Oliver Schadt is often cited by papers focused on Liver physiology and pathology (7 papers), Ubiquitin and proteasome pathways (6 papers) and Peptidase Inhibition and Analysis (4 papers). Oliver Schadt collaborates with scholars based in Germany, Italy and United States. Oliver Schadt's co-authors include Manja Friese‐Hamim, Andree Blaukat, Frank Stieber, Dieter Dorsch, Friedhelm Bladt, Michael Meyring, Ulrich Grädler, Ulrich Pehl, Claus Fittschen and Christine Knuehl and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

Oliver Schadt

17 papers receiving 315 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Oliver Schadt Germany 9 172 105 104 76 43 17 319
Tracy Lou United States 3 209 1.2× 90 0.9× 115 1.1× 57 0.8× 65 1.5× 3 334
Chunhong He United States 6 138 0.8× 86 0.8× 98 0.9× 74 1.0× 40 0.9× 21 278
Mally Romero United States 4 364 2.1× 143 1.4× 121 1.2× 53 0.7× 46 1.1× 5 475
Meizhong Xu United States 5 134 0.8× 74 0.7× 98 0.9× 75 1.0× 43 1.0× 5 295
Magdi Moussa United States 4 206 1.2× 100 1.0× 162 1.6× 89 1.2× 80 1.9× 5 382
Leslie Hall United States 4 104 0.6× 70 0.7× 98 0.9× 74 1.0× 40 0.9× 7 211
Matthew T. DiMare United States 6 190 1.1× 130 1.2× 44 0.4× 56 0.7× 32 0.7× 7 320
Heiko Krissel Germany 10 183 1.1× 99 0.9× 86 0.8× 73 1.0× 70 1.6× 17 303
Abhilasha Nair United States 7 64 0.4× 107 1.0× 39 0.4× 49 0.6× 29 0.7× 11 262
Naoto Ohi Japan 12 276 1.6× 169 1.6× 50 0.5× 30 0.4× 53 1.2× 19 519

Countries citing papers authored by Oliver Schadt

Since Specialization
Citations

This map shows the geographic impact of Oliver Schadt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Schadt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Schadt more than expected).

Fields of papers citing papers by Oliver Schadt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver Schadt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Schadt. The network helps show where Oliver Schadt may publish in the future.

Co-authorship network of co-authors of Oliver Schadt

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Schadt. A scholar is included among the top collaborators of Oliver Schadt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Schadt. Oliver Schadt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Albers, Joachim, Manja Friese‐Hamim, Oliver Schadt, et al.. (2023). The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations. Molecular Cancer Therapeutics. 22(7). 833–843. 10 indexed citations
2.
Schwarz, Dániel, et al.. (2022). Differences in Sustained Cellular Effects of MET inhibitors Are Driven by Prolonged Target Engagement and Lysosomal Retention. Molecular Pharmacology. 103(2). 77–88. 3 indexed citations
3.
Sanderson, Michael P., Manja Friese‐Hamim, Michael Busch, et al.. (2021). M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models. Molecular Cancer Therapeutics. 20(8). 1378–1387. 30 indexed citations
4.
Klein, Markus, Michael Busch, Manja Friese‐Hamim, et al.. (2021). Structure-Based Optimization and Discovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit LMP7 (β5i). Journal of Medicinal Chemistry. 64(14). 10230–10245. 27 indexed citations
5.
6.
7.
Klein, Markus, Michael P. Busch, Christina Esdar, et al.. (2019). Abstract LB-054: Discovery and profiling of M3258, a potent and selective LMP7 inhibitor demonstrating high efficacy in multiple myeloma models. LB–54. 2 indexed citations
8.
Klein, Markus, Michael Busch, Christina Esdar, et al.. (2019). Abstract LB-054: Discovery and profiling of M3258, a potent and selective LMP7 inhibitor demonstrating high efficacy in multiple myeloma models. Cancer Research. 79(13_Supplement). LB–54. 6 indexed citations
9.
Chakedis, Jeffery, Randall P. French, Michele Babicky, et al.. (2016). Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeutics. Oncotarget. 7(29). 45959–45975. 24 indexed citations
10.
Dorsch, Dieter, Oliver Schadt, Frank Stieber, et al.. (2015). Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 25(7). 1597–1602. 68 indexed citations
11.
Bladt, Friedhelm, Manja Friese‐Hamim, Christine Knuehl, et al.. (2013). EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors. Clinical Cancer Research. 19(11). 2941–2951. 114 indexed citations
12.
Berger, Michael L., et al.. (2012). Exploring the Polyamine Regulatory Site of the NMDA Receptor: a Parallel Synthesis Approach. ChemMedChem. 8(1). 82–94. 8 indexed citations
13.
Bladt, Friedhelm, Andree Blaukat, Dieter Dorsch, et al.. (2011). Abstract 2786: Identification and preclinical characterization of EMD 1204831 – A selective c-Met kinase inhibitor in clinical phase 1. Cancer Research. 71(8_Supplement). 2786–2786. 2 indexed citations
14.
Bladt, Friedhelm, Andree Blaukat, Dieter Dorsch, et al.. (2010). Abstract 3622: Preclinical characterization of EMD1214063, a potent and highly selective inhibitor of the c-Met kinase in Phase I clinical trials. Cancer Research. 70(8_Supplement). 3622–3622. 4 indexed citations
15.
Schadt, Oliver, Dieter Dorsch, Frank Stieber, et al.. (2010). 216 Preclinical characterization of EMD 1214063 - a selective c-Met kinase inhibitor in clinical phase 1. European Journal of Cancer Supplements. 8(7). 71–71. 1 indexed citations
16.
Schadt, Oliver, Friedhelm Bladt, Andree Blaukat, et al.. (2010). Abstract 5777: EMD 1214063, an exquisitely selective c-Met kinase inhibitor in clinical phase 1. Cancer Research. 70(8_Supplement). 5777–5777. 1 indexed citations
17.
Schadt, Oliver, et al.. (2006). New polyamine-sensitive inhibitors of the NMDA receptor: Syntheses and pharmacological evaluation. European Journal of Medicinal Chemistry. 42(2). 175–197. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tracy Lou Breakdown of academic impact, for papers by Chunhong He Breakdown of academic impact, for papers by Mally Romero Breakdown of academic impact, for papers by Meizhong Xu Breakdown of academic impact, for papers by Magdi Moussa Breakdown of academic impact, for papers by Leslie Hall Breakdown of academic impact, for papers by Matthew T. DiMare Breakdown of academic impact, for papers by Heiko Krissel Breakdown of academic impact, for papers by Abhilasha Nair Breakdown of academic impact, for papers by Naoto Ohi
Rankless by CCL
2026